Weiss Ratings Reiterates "Hold (C)" Rating for Amneal Pharmaceuticals (NASDAQ:AMRX)

Key Points

• Weiss Ratings has reiterated a "Hold (C)" rating for Amneal Pharmaceuticals (NASDAQ: AMRX) in a recent research report.
• JPMorgan Chase & Co. raised their target price for Amneal shares from $12.00 to $14.00, maintaining an "overweight" rating.
• Amneal Pharmaceuticals has a current market capitalization of $3.31 billion and reported earnings of $0.21 per share for the last quarter.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report)'s stock had its "hold (c)" rating reiterated by investment analysts at Weiss Ratings in a research report issued on Friday,Weiss Ratings reports.

Separately, JPMorgan Chase & Co. boosted their target price on shares of Amneal Pharmaceuticals from $12.00 to $14.00 and gave the company an "overweight" rating in a report on Tuesday, September 16th. Four analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, Amneal Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $12.00.

Amneal Pharmaceuticals Price Performance

NASDAQ AMRX traded up $0.13 during trading hours on Friday, hitting $10.55. 361,731 shares of the company's stock traded hands, compared to its average volume of 1,657,901. The company has a market capitalization of $3.31 billion, a PE ratio of 1,055.56 and a beta of 1.18. The firm's 50-day moving average is $9.84 and its 200-day moving average is $8.49. Amneal Pharmaceuticals has a 52-week low of $6.68 and a 52-week high of $10.68.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last posted its earnings results on Monday, July 21st. The company reported $0.21 earnings per share for the quarter. The company had revenue of $695.42 million for the quarter. Amneal Pharmaceuticals had a net margin of 0.12% and a negative return on equity of 189.49%. Amneal Pharmaceuticals has set its Q2 2025 guidance at EPS. Equities research analysts predict that Amneal Pharmaceuticals will post 0.53 earnings per share for the current fiscal year.

Insider Activity at Amneal Pharmaceuticals

In other news, Director John Kiely sold 32,000 shares of the company's stock in a transaction that occurred on Wednesday, August 27th. The shares were sold at an average price of $9.23, for a total value of $295,360.00. Following the transaction, the director directly owned 225,433 shares in the company, valued at approximately $2,080,746.59. This represents a 12.43% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Nikita Shah sold 114,492 shares of the company's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $9.66, for a total transaction of $1,105,992.72. Following the completion of the transaction, the executive vice president owned 152,743 shares in the company, valued at approximately $1,475,497.38. This represents a 42.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 609,206 shares of company stock valued at $5,700,625. 26.56% of the stock is owned by insiders.

Institutional Investors Weigh In On Amneal Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in Amneal Pharmaceuticals by 6.2% during the 1st quarter. Vanguard Group Inc. now owns 15,762,727 shares of the company's stock worth $132,092,000 after buying an additional 920,758 shares in the last quarter. Rubric Capital Management LP lifted its stake in shares of Amneal Pharmaceuticals by 9.1% in the 2nd quarter. Rubric Capital Management LP now owns 11,710,332 shares of the company's stock worth $94,737,000 after acquiring an additional 974,355 shares during the period. Nantahala Capital Management LLC lifted its stake in shares of Amneal Pharmaceuticals by 14.7% in the second quarter. Nantahala Capital Management LLC now owns 4,367,438 shares of the company's stock valued at $35,333,000 after purchasing an additional 558,877 shares during the period. BlackBarn Capital Partners LP lifted its stake in shares of Amneal Pharmaceuticals by 19.6% in the second quarter. BlackBarn Capital Partners LP now owns 3,446,570 shares of the company's stock valued at $27,883,000 after purchasing an additional 564,916 shares during the period. Finally, Acadian Asset Management LLC increased its holdings in Amneal Pharmaceuticals by 2.5% during the 2nd quarter. Acadian Asset Management LLC now owns 2,662,524 shares of the company's stock valued at $21,525,000 after acquiring an additional 64,230 shares in the last quarter. 31.82% of the stock is currently owned by institutional investors and hedge funds.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.